Cetrorelix

AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prosta...

Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

...xoSmithKline's tamsulosin/dutasteride fixed-dose combination Duodart will likely increase compliance, while Aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and Aeterna Zentaris/Spectrum Pharmaceuticals/Nippon Kayaku's ozarelix both aim to reduce the size of the prostate and slow disease progression. Addit...

AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results

... Signing of partnership with sanofi-aventis for cetrorelix in benign prostatic hyperplasia ("BPH") for the U....ting double-digit royalties on future net sales of cetrorelix for BPH in the U.S.; - Sanofi-aventis re... The Company retained certain rights to co-promote cetrorelix for BPH in the U.S. Juergen Engel, Ph....

A New Therapy to Protect Cancer Patients Against Infertility

...ing the time that chemotherapy was administered, and hence protect them from the effect of the drugs. The women were given the GnRH antagonist cetrorelix by 3 subcutaneous injections, each of them four days apart, concurrently with their chemotherapy. The scientists observed that there was evide...

Cetrorelix in Medical Technology

AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial

Cetrorelix showed good safety and tolerability profile Reduction of testosterone concentration was maintained above castration level Japanese partner Shionogi initiates Phase 2b trial QUEBEC CITY, March 22, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. along with its Japanese partner Shionog...

AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting

...ook forward to seeing further results from the fully-enrolled Phase 2b trial, said David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris. "With cetrorelix in an ongoing Phase 3 program and ozarelix completing a Phase 2b trial this year, we are fortunate to be leading the LHRH antagonist class with two ve...

Cetrorelix in Biological Technology

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient follow-up in the open-label safety study (study 041) of its Phase 3 program in benign prostatic...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign...

AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia

All amounts are in US dollars QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement ...

AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's second efficacy trial of its Phase 3 program in b...

AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal

QUEBEC CITY, May 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the article titled "Placebo-controlled dose-ranging Phase 2 study of subcutaneously administered LHR...

AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan

QUEBEC CITY, April 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Prof. Frans M.J. Debruyne, M.D., Ph.D., Chairman and CEO of Andros Men's Health Institutes in The ...

AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported the completion of patient recruitment for the Company's first efficacy trial of its Phase 3 program in b...

Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia

QUEBEC CITY, March 26 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced with its flagship product candidate, cetrorelix, the Company's lead luteinizing hor...

AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results

... - March - Patient dosing commenced with cetrorelix in the second efficacy study of the Phase ...x. - May - First patients treated with cetrorelix for the safety trial of the Phase 3 progra...efficacy trial of the Phase 3 program with cetrorelix in BPH. - Initiation of the second stage of...

AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners

...States in 2001. Cetrotide(R) is currently marketed worldwide by Merck Serono, except for Japan where it is marketed by Nippon Kayaku and Shionogi. cetrorelix is also currently in a Phase 3 program in benign prostatic hyperplasia involving 1,500 patients in North America and Europe. First results are expecte...